Duloxetine: a review of its pharmacology and use in chronic pain management.
Identifieur interne : 005646 ( Main/Exploration ); précédent : 005645; suivant : 005647Duloxetine: a review of its pharmacology and use in chronic pain management.
Auteurs : Geoff A. Bellingham [Canada] ; Philip W H. PengSource :
- Regional anesthesia and pain medicine [ 1532-8651 ]
English descriptors
- KwdEn :
- Adrenergic Uptake Inhibitors (administration & dosage), Adrenergic Uptake Inhibitors (adverse effects), Adrenergic Uptake Inhibitors (economics), Adrenergic Uptake Inhibitors (pharmacokinetics), Adrenergic Uptake Inhibitors (pharmacology), Adrenergic Uptake Inhibitors (therapeutic use), Analgesics, Non-Narcotic (administration & dosage), Analgesics, Non-Narcotic (adverse effects), Analgesics, Non-Narcotic (economics), Analgesics, Non-Narcotic (pharmacokinetics), Analgesics, Non-Narcotic (pharmacology), Analgesics, Non-Narcotic (therapeutic use), Antidepressive Agents (administration & dosage), Antidepressive Agents (adverse effects), Antidepressive Agents (economics), Antidepressive Agents (pharmacokinetics), Antidepressive Agents (pharmacology), Antidepressive Agents (therapeutic use), Chronic Disease, Cost-Benefit Analysis, Duloxetine Hydrochloride, Headache (drug therapy), Humans, Neuralgia (drug therapy), Osteoarthritis (drug therapy), Pain (drug therapy), Parkinson Disease (drug therapy), Randomized Controlled Trials as Topic, Serotonin Uptake Inhibitors (administration & dosage), Serotonin Uptake Inhibitors (adverse effects), Serotonin Uptake Inhibitors (economics), Serotonin Uptake Inhibitors (pharmacokinetics), Serotonin Uptake Inhibitors (pharmacology), Serotonin Uptake Inhibitors (therapeutic use), Thiophenes (administration & dosage), Thiophenes (adverse effects), Thiophenes (economics), Thiophenes (pharmacokinetics), Thiophenes (pharmacology), Thiophenes (therapeutic use).
- MESH :
- chemical , administration & dosage : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- chemical , adverse effects : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- chemical , economics : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- chemical , pharmacokinetics : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- chemical , pharmacology : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- chemical , therapeutic use : Adrenergic Uptake Inhibitors, Analgesics, Non-Narcotic, Antidepressive Agents, Serotonin Uptake Inhibitors, Thiophenes.
- drug therapy : Headache, Neuralgia, Osteoarthritis, Pain, Parkinson Disease.
- Chronic Disease, Cost-Benefit Analysis, Duloxetine Hydrochloride, Humans, Randomized Controlled Trials as Topic.
Abstract
Duloxetine is a serotonin and norepinephrine reuptake inhibitor that possesses antidepressant and pain-relieving properties. Compared with other antidepressants, it has a high affinity for both norepinephrine and serotonin reuptake transporters, which are relatively balanced. Analgesic onset has been observed within the first week of administration in randomized controlled trials and is likely obtained by enhancing the tone of the descending pain inhibition pathways of the central nervous system. Randomized trials have documented significant analgesic effects for managing chronic pain associated with fibromyalgia and diabetic peripheral neuropathic pain. Studies have also suggested that pain associated with major depressive disorder can be reduced with this medication. Modest effects for headache, osteoarthritic pain, and pain secondary to Parkinson disease have also been documented, but data are obtained from single-blinded or open-label trials that require further corroboration with larger randomized studies. Duloxetine has not yet been directly compared with other antidepressants or anticonvulsants for the treatment of pain syndromes.
DOI: 10.1097/AAP.0b013e3181df2645
PubMed: 20921842
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D59
- to stream PubMed, to step Curation: 000D59
- to stream PubMed, to step Checkpoint: 000D59
- to stream Ncbi, to step Merge: 000D50
- to stream Ncbi, to step Curation: 000D50
- to stream Ncbi, to step Checkpoint: 000D50
- to stream Main, to step Merge: 006063
- to stream Main, to step Curation: 005646
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Duloxetine: a review of its pharmacology and use in chronic pain management.</title><author><name sortKey="Bellingham, Geoff A" sort="Bellingham, Geoff A" uniqKey="Bellingham G" first="Geoff A" last="Bellingham">Geoff A. Bellingham</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Peng, Philip W H" sort="Peng, Philip W H" uniqKey="Peng P" first="Philip W H" last="Peng">Philip W H. Peng</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2010 May-Jun</MedlineDate></PubDate></date><idno type="RBID">pubmed:20921842</idno><idno type="pmid">20921842</idno><idno type="doi">10.1097/AAP.0b013e3181df2645</idno><idno type="wicri:Area/PubMed/Corpus">000D59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D59</idno><idno type="wicri:Area/PubMed/Curation">000D59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D59</idno><idno type="wicri:Area/PubMed/Checkpoint">000D59</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D59</idno><idno type="wicri:Area/Ncbi/Merge">000D50</idno><idno type="wicri:Area/Ncbi/Curation">000D50</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D50</idno><idno type="wicri:Area/Main/Merge">006063</idno><idno type="wicri:Area/Main/Curation">005646</idno><idno type="wicri:Area/Main/Exploration">005646</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Duloxetine: a review of its pharmacology and use in chronic pain management.</title><author><name sortKey="Bellingham, Geoff A" sort="Bellingham, Geoff A" uniqKey="Bellingham G" first="Geoff A" last="Bellingham">Geoff A. Bellingham</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Peng, Philip W H" sort="Peng, Philip W H" uniqKey="Peng P" first="Philip W H" last="Peng">Philip W H. Peng</name></author></analytic><series><title level="j">Regional anesthesia and pain medicine</title><idno type="eISSN">1532-8651</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Uptake Inhibitors (administration & dosage)</term><term>Adrenergic Uptake Inhibitors (adverse effects)</term><term>Adrenergic Uptake Inhibitors (economics)</term><term>Adrenergic Uptake Inhibitors (pharmacokinetics)</term><term>Adrenergic Uptake Inhibitors (pharmacology)</term><term>Adrenergic Uptake Inhibitors (therapeutic use)</term><term>Analgesics, Non-Narcotic (administration & dosage)</term><term>Analgesics, Non-Narcotic (adverse effects)</term><term>Analgesics, Non-Narcotic (economics)</term><term>Analgesics, Non-Narcotic (pharmacokinetics)</term><term>Analgesics, Non-Narcotic (pharmacology)</term><term>Analgesics, Non-Narcotic (therapeutic use)</term><term>Antidepressive Agents (administration & dosage)</term><term>Antidepressive Agents (adverse effects)</term><term>Antidepressive Agents (economics)</term><term>Antidepressive Agents (pharmacokinetics)</term><term>Antidepressive Agents (pharmacology)</term><term>Antidepressive Agents (therapeutic use)</term><term>Chronic Disease</term><term>Cost-Benefit Analysis</term><term>Duloxetine Hydrochloride</term><term>Headache (drug therapy)</term><term>Humans</term><term>Neuralgia (drug therapy)</term><term>Osteoarthritis (drug therapy)</term><term>Pain (drug therapy)</term><term>Parkinson Disease (drug therapy)</term><term>Randomized Controlled Trials as Topic</term><term>Serotonin Uptake Inhibitors (administration & dosage)</term><term>Serotonin Uptake Inhibitors (adverse effects)</term><term>Serotonin Uptake Inhibitors (economics)</term><term>Serotonin Uptake Inhibitors (pharmacokinetics)</term><term>Serotonin Uptake Inhibitors (pharmacology)</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Thiophenes (administration & dosage)</term><term>Thiophenes (adverse effects)</term><term>Thiophenes (economics)</term><term>Thiophenes (pharmacokinetics)</term><term>Thiophenes (pharmacology)</term><term>Thiophenes (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Uptake Inhibitors</term><term>Analgesics, Non-Narcotic</term><term>Antidepressive Agents</term><term>Serotonin Uptake Inhibitors</term><term>Thiophenes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Headache</term><term>Neuralgia</term><term>Osteoarthritis</term><term>Pain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Chronic Disease</term><term>Cost-Benefit Analysis</term><term>Duloxetine Hydrochloride</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Duloxetine is a serotonin and norepinephrine reuptake inhibitor that possesses antidepressant and pain-relieving properties. Compared with other antidepressants, it has a high affinity for both norepinephrine and serotonin reuptake transporters, which are relatively balanced. Analgesic onset has been observed within the first week of administration in randomized controlled trials and is likely obtained by enhancing the tone of the descending pain inhibition pathways of the central nervous system. Randomized trials have documented significant analgesic effects for managing chronic pain associated with fibromyalgia and diabetic peripheral neuropathic pain. Studies have also suggested that pain associated with major depressive disorder can be reduced with this medication. Modest effects for headache, osteoarthritic pain, and pain secondary to Parkinson disease have also been documented, but data are obtained from single-blinded or open-label trials that require further corroboration with larger randomized studies. Duloxetine has not yet been directly compared with other antidepressants or anticonvulsants for the treatment of pain syndromes.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Peng, Philip W H" sort="Peng, Philip W H" uniqKey="Peng P" first="Philip W H" last="Peng">Philip W H. Peng</name></noCountry><country name="Canada"><noRegion><name sortKey="Bellingham, Geoff A" sort="Bellingham, Geoff A" uniqKey="Bellingham G" first="Geoff A" last="Bellingham">Geoff A. Bellingham</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005646 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005646 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20921842
|texte= Duloxetine: a review of its pharmacology and use in chronic pain management.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20921842" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |